A citation-based method for searching scientific literature

Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L Aisner, Mary Beth Beasley, Alain C Borczuk, Philip T Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P Hariri, Izidor Kern, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Teodora Radonic, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Prudence Russell, Frank Schneider, Lynette M Sholl, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe. Arch Pathol Lab Med 2018
Times Cited: 47







List of co-cited articles
355 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
720
31

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Jonas J Heymann, William A Bulman, David Swinarski, Carlos A Pagan, John P Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B Stoopler, Joshua R Sonett, Adrian G Sacher,[...]. Cancer Cytopathol 2017
115
25


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
23

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
23

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Joseph McLaughlin, Gang Han, Kurt A Schalper, Daniel Carvajal-Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy Herbst, Patricia LoRusso, David L Rimm. JAMA Oncol 2016
472
21

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
112
21

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
19

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
David L Rimm, Gang Han, Janis M Taube, Eunhee S Yi, Julia A Bridge, Douglas B Flieder, Robert Homer, William W West, Hong Wu, Anja C Roden,[...]. JAMA Oncol 2017
433
19

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Marianne J Ratcliffe, Alan Sharpe, Anita Midha, Craig Barker, Marietta Scott, Paul Scorer, Hytham Al-Masri, Marlon C Rebelatto, Jill Walker. Clin Cancer Res 2017
204
17

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
17

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Lynette M Sholl, Heather Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi A Jänne, Scott J Rodig. Am J Surg Pathol 2013
111
17

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
17


Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.
Patrick L Fitzgibbons, Linda A Bradley, Lisa A Fatheree, Randa Alsabeh, Regan S Fulton, Jeffrey D Goldsmith, Thomas S Haas, Rouzan G Karabakhtsian, Patti A Loykasek, Monna J Marolt,[...]. Arch Pathol Lab Med 2014
150
17

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
14


Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
14

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.
Murry W Wynes, Lynette M Sholl, Manfred Dietel, Ed Schuuring, Ming S Tsao, Yasushi Yatabe, Raymond R Tubbs, Fred R Hirsch. J Thorac Oncol 2014
116
12

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, Didier Debieuvre, Jean Mosser, Hervé Lena, L'Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel,[...]. Lancet 2016
469
12

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
A J van der Wekken, R Pelgrim, N 't Hart, N Werner, M F Mastik, L Hendriks, E H F M van der Heijden, M Looijen-Salamon, A J de Langen, J Staal-van den Brekel,[...]. Clin Cancer Res 2017
43
13

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Hans Brunnström, Anna Johansson, Sofia Westbom-Fremer, Max Backman, Dijana Djureinovic, Annika Patthey, Martin Isaksson-Mettävainio, Miklos Gulyas, Patrick Micke. Mod Pathol 2017
95
12


Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Akihiko Yoshida, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Hisao Asamura, Tatsuhiro Shibata, Koh Furuta, Takashi Kohno, Ryoji Kushima. Mod Pathol 2014
87
12


Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Bryce Noll, Wei-Lien Wang, Yun Gong, Jun Zhao, Neda Kalhor, Victor Prieto, Gregg Staerkel, Sinchita Roy-Chowdhuri. Cancer Cytopathol 2018
72
12

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming Sound Tsao, Keith M Kerr, Mark Kockx, Mary-Beth Beasley, Alain C Borczuk, Johan Botling, Lukas Bubendorf, Lucian Chirieac, Gang Chen, Teh-Ying Chou,[...]. J Thorac Oncol 2018
310
12

ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen.
Merdol Ibrahim, Suzanne Parry, Dawn Wilkinson, Neil Bilbe, David Allen, Steven Forrest, Perry Maxwell, Anthony O'Grady, Jane Starczynski, Philippe Tanier,[...]. J Thorac Oncol 2016
28
17

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
Marina Pekar-Zlotin, Fred R Hirsch, Lior Soussan-Gutman, Maya Ilouze, Addie Dvir, Theresa Boyle, Murry Wynes, Vincent A Miller, Doron Lipson, Gary A Palmer,[...]. Oncologist 2015
109
10


Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Andreas H Scheel, Manfred Dietel, Lukas C Heukamp, Korinna Jöhrens, Thomas Kirchner, Simone Reu, Josef Rüschoff, Hans-Ulrich Schildhaus, Peter Schirmacher, Markus Tiemann,[...]. Mod Pathol 2016
247
10

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Marlon C Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E Steele, Paul B Robbins, John A Blake-Haskins,[...]. Diagn Pathol 2016
121
10


PD-L1 IHC in NSCLC with a global and methodological perspective.
Erik Thunnissen, Adrianus J de Langen, Egbert F Smit. Lung Cancer 2017
24
20

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho,[...]. PLoS One 2014
50
10

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Reinhard Büttner, John R Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth J Bloom, Manfred Dietel, John W Longshore, Fernando López-Ríos, Frédérique Penault-Llorca,[...]. J Clin Oncol 2017
219
10

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
10

Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Marius Ilie, Jonathan Juco, Lingkang Huang, Veronique Hofman, Shirin Khambata-Ford, Paul Hofman. Cancer Cytopathol 2018
58
10

Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review.
Deepali Jain, Sinchita Roy-Chowdhuri. Arch Pathol Lab Med 2018
41
12

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
J Adam, N Le Stang, I Rouquette, A Cazes, C Badoual, H Pinot-Roussel, L Tixier, C Danel, F Damiola, D Damotte,[...]. Ann Oncol 2018
124
10


Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
25
20

Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Qiushi Wang, Lianhua Zhao, Xin Yang, Shirong Wei, Ying Zeng, Chengyi Mao, Li Lin, Ping Fu, Liang Lyu, Zengpeng Li,[...]. Lung Cancer 2016
10
40

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Antonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, Manuela Iezzi, Lara Felicioni, Tommaso D'Antuono, Giampaolo Filice, Luigi Guetti, Felice Mucilli, Fiamma Buttitta. J Thorac Oncol 2016
89
8

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
8

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Greta Alì, Agnese Proietti, Serena Pelliccioni, Cristina Niccoli, Cristiana Lupi, Elisa Sensi, Riccardo Giannini, Nicla Borrelli, Maura Menghi, Antonio Chella,[...]. Arch Pathol Lab Med 2014
70
8

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
217
8


Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Nir Peled, Gary Palmer, Fred R Hirsch, Murry W Wynes, Maya Ilouze, Marileila Varella-Garcia, Lior Soussan-Gutman, Geoff A Otto, Philip J Stephens, Jeffrey S Ross,[...]. J Thorac Oncol 2012
105
8

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Noemí Reguart, Cristina Teixidó, Ana Giménez-Capitán, Laia Paré, Patricia Galván, Santiago Viteri, Sonia Rodríguez, Vicente Peg, Erika Aldeguer, Nuria Viñolas,[...]. Clin Chem 2017
38
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.